Xiangwei Xu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Molecular Docking

Signaling Pathway

Lipopolysaccharide Induced

Histone Deacetylase

Top Venues

Evidence-based complementary and alternative medicine : eCAM

Stem cells international

ACS medicinal chemistry letters

This page only lists publications with an associated author ORCID identifier.

Publications

Junyi Yang, Yanwen He, Youkun Kang, Liteng Shen, Wen Zhang, Yumeng Yan, Xinyi Li, Wenhai Huang, Xiangwei Xu
Virtual Screening and Molecular Docking: Discovering Novel METTL3 Inhibitors. ACS medicinal chemistry letters 15 (9) (2024)
Ji Ma, Ruya Li, Fang Xu, Fang Zhu, Xiangwei Xu
Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study. Evidence-based complementary and alternative medicine : eCAM 2023 (2023)
Wenchun Zeng, Xiangwei Xu, Fang Xu, Fang Zhu, Yuecui Li, Ji Ma
Exploring Key Genes with Diagnostic Value for Nonalcoholic Steatohepatitis Based on Bioinformatics Analysis. ACS omega 8 (23) (2023)
Ji Ma, Ruya Li, Fang Xu, Fang Zhu, Xiangwei Xu
Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study. Evidence-based complementary and alternative medicine : eCAM 2023 (2023)
Li Xiong, Lingyu She, Jinfeng Sun, Xiangwei Xu, Liwei Li, Yuqing Zeng, Hao Tang, Guang Liang, Wei Wang, Xia Zhao
Isolinderalactone Ameliorates the Pathology of Alzheimer's Disease by Inhibiting the JNK Signaling Pathway. Journal of natural products (2023)
Yongpan Li, Jujia Zheng, Qiang Huo, Zhongchao Chen, Jun Chen, Xiangwei Xu
Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation. Stem cells international 2022 (2022)